Stay updated on Subcutaneous Durvalumab in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-10-31T15:41:49.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A site-wide NIH notice says federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    0.6%
    Check dated 2026-10-24T15:52:19.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-17T15:39:10.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer revision label updated from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-10T15:44:48.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    A new revision entry, v3.7.0, has been added to the study record history. The previous entry, v3.6.6, has been removed, updating the record's version history.
    Difference
    0.1%
    Check dated 2026-09-19T18:02:00.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The Record History page lists a new Revision: v3.6.6, replacing v3.6.5, indicating a software/UI update to the history display.
    Difference
    0.1%
    Check dated 2026-08-29T20:58:14.000Z thumbnail image

Stay in the know with updates to Subcutaneous Durvalumab in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.